Last reviewed 2026-05-31 · How we verify

GL0034 Dose Level 6

Sun Pharmaceutical Industries Limited · Phase 2 active Small molecule ✓ Verified May 2026 Quality 10/100

GL0034 Dose Level 6 is a Small molecule drug developed by Sun Pharmaceutical Industries Limited. It is currently in Phase 2 development.

GL0034 Dose Level 6 was not mentioned in the provided facts. However, based on the information available, GL0034 is being studied in a Phase II trial for Type II Diabetes Mellitus, with dose levels 1, 2, and 3 being tested.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	GL0034 Dose Level 6
Sponsor	Sun Pharmaceutical Industries Limited
Modality	Small molecule
Phase	Phase 2

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GL0034 Dose Level 6 CI brief — competitive landscape report
GL0034 Dose Level 6 updates RSS · CI watch RSS
Sun Pharmaceutical Industries Limited portfolio CI

Frequently asked questions about GL0034 Dose Level 6

What is GL0034 Dose Level 6?

GL0034 Dose Level 6 is a Small molecule drug developed by Sun Pharmaceutical Industries Limited.

Who makes GL0034 Dose Level 6?

GL0034 Dose Level 6 is developed by Sun Pharmaceutical Industries Limited (see full Sun Pharmaceutical Industries Limited pipeline at /company/sun-pharmaceutical-industries-limited).

What development phase is GL0034 Dose Level 6 in?

GL0034 Dose Level 6 is in Phase 2.

Manufacturer: Sun Pharmaceutical Industries Limited — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing